MCAM and ovarian carcinoma: Since METCAM/MUC18 is expressed at a higher level in the carcinoma than residual disease, it was suggested to be useful for prognosticating tumor relapse and as a self-reliant predicting marker for poor prognosis of ovarian carcinoma [18].